(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
World’s tallest bridge and biggest museum named ‘greatest places of 2026’ - 2Figure out how to Put resources into Lab Precious stones: A Novice's Aide
- 3Fireball sightings are surging across the US — here's what's really going on
- 4James Webb Space Telescope's mysterious 'little red dots' may be black holes in disguise
- 5Wedding trip Objections in the US
- EU agrees on agriculture safeguards as fronts harden in Mercosur deal
- I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- Under pressure at home, Belgium's leader treads a tight rope with EU partners over funds for Ukraine
- Step by step instructions to Recognize the Distinction Between Lab Jewels and Precious stone Simulants
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- The most effective method to Pick The Right Speakers
- Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- The Best Web-based Courses for Expertise Improvement
